Press Releases

BIOMS MEDICAL TO PRESENT AT THE MS SOCIETY OF CANADA, ALBERTA DIVISION’S AGM AND THE RODMAN & RENSHAW 8TH ANNUAL HEALTHCARE CONFERENCE

Edmonton, Alberta, November 3, 2006 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the MS Society of Canada, Alberta Division’s Annual General Meeting in Calgary, Alberta.

WHEN: Saturday, November 4th at 1:10 pm (Mountain Time)
WHERE: Greenwood Inn, Calgary, Alberta

About The MS Society of Canada – Alberta Division

Founded in 1980, the Alberta Division office is located in Edmonton, Alberta. The mission of the Multiple Sclerosis Society of Canada is: To be a leader in finding a cure for multiple sclerosis and enabling people affected by MS to enhance their quality of life. For more information visit www.mssociety.ca.

Mr. Giese will also present at the Rodman & Renshaw 8th Annual Healthcare Conference in New York.

WHEN: Monday, November 6th at 11:20 am (Eastern Time)
WHERE: New York Palace Hotel, 455 Madison Avenue, New York

About Rodman & Renshaw Healthcare Conference

The Conference will be attended by investors, venture capitalists, company executives, scientists and other industry leaders. For more information visit www.rodmanandrenshaw.com.

This press release may contain forward-looking statements, which reflect the Corporation’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation’s ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide (MBP8298) will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.